Quest Diagnostics director adds shares via DRIP

Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share.

Rhea-AI Filing Summary

Quest Diagnostics director Wright Lassiter III reported acquiring 7 shares of common stock on January 28, 2026 at $183.51 per share. The filing states these shares were obtained through a broker-administered dividend reinvestment plan and are eligible for deferred reporting under Rule 16a-6, but were reported early on Form 4. Following this small acquisition, his directly held position increased to 9,057 shares, a figure that includes shares previously acquired via dividend reinvestment since his last Form 4 filing.

Insider Trade Summary

Small Acquisition: 7 shares

Small Acquisition 1 txn

Insider Lassiter Wright III

Role Director

Type	Security	Shares	Price	Value
Small Acquisition	Common Stock	7	$183.51	$1K

Holdings After Transaction: Common Stock — 9,057 shares (Direct)

Footnotes (2)

1. F1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.
2. F2. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What insider transaction did Quest Diagnostics (DGX) report for Wright Lassiter III?

Quest Diagnostics reported that director Wright Lassiter III acquired 7 shares of common stock. The shares were obtained through a broker-administered dividend reinvestment plan and reported early on Form 4, even though they were eligible for deferred reporting under SEC Rule 16a-6.

At what price did the Quest Diagnostics (DGX) director acquire shares in this Form 4?

The director acquired 7 Quest Diagnostics common shares at a price of $183.51 per share. This transaction reflects automatic dividend reinvestment rather than an open-market purchase, as described in the filing’s footnotes regarding the broker-administered dividend reinvestment plan.

How many Quest Diagnostics (DGX) shares does Wright Lassiter III hold after this transaction?

After this transaction, Wright Lassiter III directly holds 9,057 Quest Diagnostics common shares. The filing explains that this amount includes shares acquired through dividend reinvestment since his last Form 4, consolidating prior reinvested dividends into the updated ownership total.

What is the nature of the Quest Diagnostics (DGX) transaction reported under code L?

The transaction is coded “L,” described as a small acquisition under Rule 16a-6. It represents 7 shares acquired via a dividend reinvestment plan, which are eligible for deferred reporting on Form 5, though the director chose to disclose them early on Form 4.

Was the Quest Diagnostics (DGX) director’s share acquisition an open-market buy?

No, the acquisition was not an open-market purchase. The Form 4 notes that the 7 shares were acquired automatically through a dividend reinvestment plan handled by the director’s broker, rather than through discretionary buying on the open market.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 02/20/2026 - 05:08 PM EST Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Lassiter Wright III

(Last) (First) (Middle)

500 PLAZA DRIVE

C/O QUEST DIAGNOSTICS

(Street)

SECAUCUS NJ 07094

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
QUEST DIAGNOSTICS INC [ DGX ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/28/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/28/2026		L	V	7(1)	A	$183.51	9,057(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Reflects shares that were acquired pursuant to a dividend reinvestment plan administered by the reporting person's broker and eligible for deferred reporting on Form 5 under Rule 16a-6. The reporting person has chosen to report such transaction early on this Form 4.

2. The amount includes shares acquired via dividend reinvestment since the date of reporting person's last filing on Form 4.

Remarks:

	Sean D. Mersten, Attorney in Fact for Wright L. Lassiter, III	02/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.